Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Semin Cell Dev Biol. 2021 Apr 30;119:39–48. doi: 10.1016/j.semcdb.2021.04.017

Fig. 2. Schematic model for cell therapy using hiPSC-derived myogenic cells.

Fig. 2.

Successful muscle cell therapy requires transplantation of sufficient myogenic progenitors with regenerating capacity. After myogenic differentiation of hiPSCs using the aforementioned protocols, the heterogeneous cell population obtained needs to undergo purification and enrichment through cell sorting based on specific surface markers.